Pharmacokinetic interaction trial between co-artemether and mefloquine

European Journal of Pharmaceutical Sciences

Volumn 10, Issue 2, 2000, Pages 141-151

  Lefèvre, Gilbert ^a   Bindschedler, Margaretha ^a   Ezzet, Farkad ^a   Schaeffer, Nicole ^a   Meyer, Ingo ^b   Thomsen, Mikael S ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b IQVIA   (United States)

Author keywords

Artemether; Co artemether; CYP3A4; Lumefantrine; Mefloquine

Indexed keywords

ANTIMALARIAL AGENT; ARTEMETHER PLUS BENFLUMETOL; MEFLOQUINE;

ADULT; ANTIMALARIAL ACTIVITY; ARTICLE; BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

ADULT; ANTIMALARIALS; AREA UNDER CURVE; ARTEMISININS; CYTOCHROME P-450 ENZYME SYSTEM; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; ELECTROCARDIOGRAPHY; ENZYME INDUCTION; HEART; HUMANS; HYDROCORTISONE; MALE; MEFLOQUINE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; SESQUITERPENES;

EID: 0342514531     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-0987(00)00060-9     Document Type: Article

References (55)

1. Ashton M., Sy N.D., Gordi T., Hai T.N., Thach D.C., Huong N.V., Farah M.H., Johansson M., Công L.D. Evidence for time-dependent artemisinin kinetics in adult with uncomplicated malaria. Pharm. Pharmacol. Lett. 6:1996;127-130.
2. Ashton M., Hai T.N., Sy N.D., Huong D.X., van Huong N., Nieu N.T., Cong L.D. Artemisinin pharmacokinetics is time-dependent during repeated oral administration in healthy male adults. Drug Metab. Dispos. 26:1998;25-27.
3. Bangchang K., Karbwang J., Back D.J. Mefloquine metabolism by human liver microsomes. Effect of other antimalarial drugs. Biochem. Pharmacol. 43:1992;1957-1961.
4. Bergqvist Y., Hellgren U., Churchill F.C. High performance liquid chromatography assay for the simultaneous monitoring of mefloquine and its acid metabolite in biological samples using protein precipitation and ion-pair extraction. J. Chromatogr. 432:1988;253-263.
5. Bienvenu T., Rey E., Pons G., d'Athis P., Olive G. Simple non-invasive procedure for the investigation of cytochrome P450IIIA dependent enzymes in humans. Int. J. Clin. Pharmacol. Ther. Toxicol. 29:1991;441-445.
6. Bindschedler M., Degen P., Lu Z.L., Jiao X.Q., Liu G.Y., Fan F. Comparative Bioavailability of Benflumetol After Administration of Single Oral Doses of Co-artemether Under Fed and Fasted Conditions To Healthy Subjects. XIVth International Congress for Tropical Medicine and Malaria, 17-22 November, Nagasaki, Japan :1996;. Abstr. P-01-96.
7. ®) in Healthy Subjects After Single Oral Doses Given With A High Fat Meal. 2nd European Congress on Tropical Medicine, Liverpool, UK, 14-18 September :1998;. Abstr. P29.
8. Bindschedler, M., Lefèvre, G., Ezzet, F., Schaeffer, N., Meyer, I., Thomsen, M. Cardiac effects of therapeutic doses of co-artemether and mefloquine given alone and in combination to healthy volunteers. J. Clin. Pharm. (submitted).
9. Bunnag D., Viravan C., Looareesuwan S., Karbwang J., Harinasuta T. Clinical trial of artesunate and artemether on multidrug resistant falciparum malaria in Thailand. A preliminary report. Southeast Asian J. Trop. Med. Public Health. 22:1991;380-385.
10. Burstein A.H., Reiss W.G., Kantor E., Anderson G.D. Cytochrome P450 3A4 activity in premenopausal and postmenopausal women, based on 6-beta-hydroxycortisol:cortisol ratios. Pharmacotherapy. 18:1998;1271-1276.
11. Chang T.K., Yu L., Maurel P., Waxman D.J. Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction of oxazaphosphorines. Cancer Res. 57:1997;1946-1954.
12. Coleman M.D., Fleckenstein L., Heiffer M.H. Primaquine disposition in the isolated perfused rat liver: effect of mefloquine induced bile flow reduction. Biopharm. Drug Dispos. 10:1989;153-164.
13. Coyne, P.E., Ajayi, F., Harris, J., Wiley, T., Worthham, D., Cantilena, L.R., 1996. Pharmacodynamics and pharmacokinetics of halofantrine and mefloquine. American Society for Clinical Pharmacology and Therapeutics. Abstract PII-7. Clin. Pharm. Ther. Feb: 160.
14. Crevoisier C., Handschin J., Barré J., Roumenov D., Kleinbloesem C. Food increases the bioavailability of mefloquine. Eur. J. Clin. Pharmacol. 53:1997;135-139.
15. Davis T.M., Dembo L.G., Kaye-Eddie S.A., Hewitt B.J., Hislop R.G., Batty K.T. Neurological, cardiovascular and metabolic effects of mefloquine in healthy volunteers: a double-blind, placebo-controlled trial. Br. J. Clin. Pharmacol. 42:1996;415-421.
16. Ezzet F., Mull R., Karbwang J. Population pharmacokinetics and therapeutic response of CGP 56697 (artemether+benflumetol) in malaria patients. Br. J. Clin. Pharmacol. 46:1998;553-561.
17. Fonteyne W., Bauwens A., Jordaens L. Atrial flutter with 1:1 conduction after administration of the antimalarial drug mefloquine. Clin. Cardiol. 19:1996;967-968.
18. Franssen G., Rouveix B., Lebras J., Bauchet J., Verdier F., Michon C., Bricaire F. Divided-dose kinetics of mefloquine in man. Br. J. Clin. Pharmacol. 28:1989;179-184.
19. Grace J.M., Aguilar A.J., Trotman K.M., Peggins J.O., Brewer T.G. Metabolism of beta-arteether to dihydroqinghaosu by human liver microsomes and recombinant cytochrome P450. Drug Metab. Dispos. 26:1998;313-317.
20. Hatz C., Habdulla S., Mull R., Schellenberg D., Gathmann I., Kibatala P., Beck H.P., Tanner M., Royce C. Efficacy and safety of CGP 56697 (artemether and benflumetol) compared with chloroquine to treat acute falciparum malaria in Tanzanian children aged 1-5 years. Trop. Med. Int. Health. 3:1998;498-504.
21. Hien T.T., White N.J. Qinghaosu. Lancet. 341:1993;603-608.
22. Karbwang J., Bangchang K. Clinical pharmacokinetics of halofantrine. Clin. Pharmacokinet. 27:1994;104-119.
23. Karbwang J., Banchang K., Bunnag D., Harinasuta T. Pharmacokinetics and pharmacodynamics of mefloquine in Thai patients with acute falciparum malaria. Bull. World Health Organ. 69:1991;207-212.
24. Karbwang J., Bangchang K., Thanavibul A., Back D., Bunnag D., Harinasuta T. Pharmacokinetics of mefloquine alone or in combination with artesunate. Bull. WHO. 72:1994;83-87.
25. Laothavorn P., Karbwang J., Na-Bangchang K., Bunnag D., Harinasuta T. Effect of mefloquine on electrocardiographic changes in uncomplicated falciparum malaria patients. Southeast Asian J. Trop. Med. Public Health. 23:1992;51-54.
26. ®). Clin. Drug Invest. 18:1999;467-480.
27. Leo K.U., Wesche D.L., Marino M.T., Brewer T.G. Mefloquine effect on the disposition of halofantrine in the isolated perfused rat liver. J. Pharm. Pharmacol. 48:1996;723-728.
28. Lin Y., Anderson G.D., Kantor E., Ojemann L.M., Wilensky A.J. Differences in the urinary excretion of 6-β-hydroxycortisol/cortisol between asian and caucasian women. J. Clin. Pharmacol. 39:1999;578-582.
29. Looareesuwan S., Vivaran C., Vanijanonta P., Wilairatana P., Pitisuttithum P., Andrial M. Comparative clinical trial of artesunate followed by mefloquine in the treatment of uncomplicated falciparum malaria: two- and three-day regimens. Am. J. Trop. Med. Hyg. 54:1996;210-213.
30. Mansor S.M., Navaratnam V., Yahaya N., Nair N.K., Wernsdorfer W.H., Degen P.H. Determination of a new antimalarial drug, benflumetol, in blood plasma by reverse-phase high-performance liquid chromatography with ultraviolet detection. J. Chromatogr. 682:1996;321-325.
31. Monlun E., Le Metayer P., Szwandt S., Neau D., Longy-Boursier M., Horton J., Le Bras M. Cardiac complications of halofantrine: a prospective study of 20 patients. Trans. R. Soc. Trop. Med. Hyg. 89:1995;430-433.
32. Navaratnam V., Mansor S.M., Chin L.K., Mordi M.N., Asokan M., Nair N.K. Determination of artemether and dihydroartemisinin in blood plasma by HPLC for application in clinical pharmacological studies. J. Chromatogr. 669:1995;289-294.
33. Nosten F., ter Kuile F., Luxemburger C., Woodrow C., Kyle D.E., Chongsuphajaisiddhi T., White N.J. Cardiac effects of antimalarial treatment with halofantrine. Lancet. 341:1993;1054-1056.
34. Olliaro P.L., Trigg P.I. Status of antimalarial drugs under development. Bull. WHO. 73:1995;565-571.
35. Palmer K.J., Holliday S.M., Brogden R.N. Mefloquine: a review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 45:1993;430-475.
36. Pennie R.A., Koren G., Crevoisier C. Steady state pharmacokinetics of mefloquine in long-term travellers. Trans. R. Soc. Trop. Med. Hyg. 87:1993;459-462.
37. Riviere J.H., Back D.J. Inhibition of ethinylestradiol and tolbutamide metabolism by quinoline derivates in vitro. Chem. Biol. Interact. 59:1986;301-308.
38. Saenger P. 6-Beta hydroxy cortisol in random urine samples as indicator of enzyme induction. Clin. Pharmacol. Ther. 34:1983;818-821.
39. Skelton-Stroud P., Mull R. Positioning, labelling, and medical information control of co-artemether tablets (CGP 56697): a fixed novel combination of artemether and benflumetol. Med. Trop. 58:1998;77S-81S.
40. ® - A New Combination of Antimalarial. 6th Conference of the International Society of Travel Medicine, 6-10 June, Montreal, Quebec, Canada :1999;. [Abstr. C15].
41. Svensson U.S.H., Ashton M. Identification of the human cytochrome P450 enzymes involved in the in vitro metabolism of artemisinin. Br. J. Clin. Pharmacol. 48:1999;528-535.
42. Svensson U.S.H., Ashton M., Hai T.N., Bertilsson L., Huong D.X., van Huong N., Niêu T.N., Sy D.N., Lykkesfeldt J., Công L.D. Artemisinin induces omeprazole metabolism in human beings. Clin. Pharmacol. Ther. 64:1998;160-167.
43. Thomsen M.S., Lefèvre G., Ezzet F., Bindschedler M. Co-artemether: Pharmacokinetic Profile of A Combined Anti-malaria Compound Treatment. 2nd European Congress on Tropical Medicine, 14-18 September, Liverpool, UK :1998;. [Abstr. P31].
44. Toivonen L., Viitasalo M., Siikamaki H., Raatikka M., Pohjola-Sintonen S. Provocation of ventricular tachycardia by antimalarial drug halofantrine in congenital long QT syndrome. Clin. Cardiol. 17:1994;403-404.
45. Tran J.Q., Kovacs S.J., McIntosh T.S., Davis H.M., Martin D.E. Morning spot and 24-hour urinary 6β-hydroxycortisol to cortisol ratios: intraindividual variability and correlation under basal conditions and conditions of CYP 3A4 induction. J. Clin. Pharmacol. 39:1999;487-494.
46. van Agtmael M., van der Graaf C.A.A., Dien T.K., Koopmans R.P., van Boxtel C.J. The contribution of the enzymes CYP2D6 and CYP2C19 in the demethylation of artemether in healthy subjects. Eur. J. Drug Metab. Pharmacokinet. 23:1998;429-436.
47. van Agtmael M., Bouchaud O., Malvy D., Delmont J., Danis M., Barette S., Gras C., Bernard J., Touze J.E., Gathmann I., Mull R. The comparative efficacy and tolerability of CGP 56697 (artemether+lumefantrine) versus halofantrine in the treatment of uncomplicated falciparum malaria in travellers returning from the Tropics to The Netherlands and France. Int. J. Antimicrob Agents. 12:1999;159-169.
48. van Agtmael M., Cheng-Qi S., Qing J.X., Mull R., van Boxtel C.J. Multiple dose pharmacokinetics of artemether in Chinese patients with uncomplicated falciparum malaria. Int. J. Antimicrob. Agents. 12:1999;151-158.
49. van Agtmael M., Gupta V., van der Wösten T.H., Rutten J.-P.B., van Boxtel C.J. Grapefruit juice increases the bioavailability of artemether. Eur. J. Clin. Pharmacol. 55:1999;405-410.
50. van Vugt M., Brockman A., Gemperli B., Luxemburger C., Gathmann I., Royce C., Slight T., Looareesuwan S., White N.J., Nosten F. Randomized comparison of artemether-benflumetol and artesunate-mefloquine in treatment of multidrug-resistant falciparum malaria. Antimicrob. Agents Chemother. 42:1998;135-139.
51. van Vugt M., Wilairatana P., Gemperli B., Gathmann I., Phaipun L., Brockman A., Luxemburger C., White N.J., Nosten F., Looareesuwan S. Efficacy of six doses of artemether-lumefantrine (benflumetol) in multi-drug resistant falciparum malaria. Am. J. Trop. Med. Hyg. 60:1999;936-942.
52. von Seidlein L., Jaffar S., Pinder M., Haywood M., Snounou G., Gemperli B., Gathmann I., Royce C., Greenwood B. Treatment of African children with uncomplicated falciparum malaria with a new antimalarial drug, CGP 56697. J. Infect. Dis. 176:1997;1113-1116.
53. Wernsdorfer W.H. Epidemiology of drug resistance in malaria. Acta Trop. 56:1994;143-156.
54. White N.J. The treatment of malaria. New Engl. J. Med. 335:1996;800-806.
55. Zimmerlin, A., Birlinger, B., Gertsch, W., Gut, J. CYP3A4 involvement in co-artemether human in vitro metabolism. In preparation.